Under the Inflation Reduction Act’s drug pricing provisions, for the first time Medicare will soon be able to negotiate the prices of a limited subset of prescription drugs. Drug manufacturers and the investment community are worried about the impact drug price negotiations may have on the prices and corresponding revenues of certain drugs in the […]
